Julia da Penha Piccoli Rangel

Julia da Penha Piccoli Rangel

Auto-generated profile, based on publicly available information

Julia da Penha Piccoli Rangel

School of Veterinary Medicine, University of Vila Velha, Vila Velha, ES, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Veterinary Anaesthesia and Analgesia
Verified
Journal Article
Closed access
PDF file
CSClarissa R Simões
Clarissa R Simões
EMEduardo R Monteiro
Eduardo R Monteiro
JRJulia Pp Rangel
Julia Pp Rangel
JNJuarez S Nunes-Junior
Juarez S Nunes-Junior
DCDaniela Campagnol
Daniela Campagnol

1 March 2017 in Veterinary Anaesthesia and Analgesia
Verified
Journal Article
Closed access
FBFlavia S. Bitti
Flavia S. Bitti
DCDaniela Campagnol
Daniela Campagnol
JRJulia Pp. Rangel
Julia Pp. Rangel
JJJuarez S. Nunes Junior
Juarez S. Nunes Junior
BLBárbara Loureiro
Bárbara Loureiro
EMEduardo R. Monteiro
Eduardo R. Monteiro

1 April 2018 in Pesquisa Veterinária Brasileira
Verified
Journal Article
Open access
PDF file
AOAlvaro de Paula Lage De Oliveira
Alvaro de Paula Lage De Oliveira
JRJulia P.P. Rangel
Julia P.P. Rangel
VRViviane Raposo
Viviane Raposo
NPNoely G. Pianca
Noely G. Pianca
ECEmanuelle P. Cruz
Emanuelle P. Cruz
BMBetânia S. Monteiro
Betânia S. Monteiro
The present study aimed to evaluate the efficacy of mesenchymal stem cell (MSC) infusion, derived from adipose tissue, on reduction of local and remote tissue damage caused by the event of experimental intestinal I/R in New Zealand breed rabbits. For obtaining, characterization, and cultivation of MSC derived from adipose tissue (MSC-Adp), 3 juvenile animals (four months old) were used. The cells were considered to be viable for therapy after the fourth passage (in vitro phase). For the in vivo stage, 24 young adult animals (six months old) were used, weighing approximately 3.5 kg, in which were randomly divided into two groups, called: IR treated with MSC (I2H/R5H MSC 3D; I2H/R5H MSC 7D); IR treated with PBS (I2H/R5H PBS 3D; I2H/R5H PBS 7D). The animals were anesthetized and submitted to pre-retro-umbilical midline celiotomy. The extramural peri-intestinal marginal artery was located and clamped (predetermined and standardized region) with the aid of a vascular clip, promoting a 2 hour blood flow interruption. After this period, blood flow was reestablished, inhalatory anesthesia was suspended, and the animals awaken. After 5 hours of reperfusion, the treatments were performed by intravenous infusion according to the experimental groups. The animals were evaluated 72 hours and seven days after the treatment as for the macroscopic appearance (color and peristaltism) of the jejunal segment, and by histological evaluation of the ischemic segment for the presence or absence of destruction of the intestinal mucosa, edema, bleeding, dilation of lymph vessels, and presence of polymorphonuclear inflammatory cells, both in the mucosa and submucosa. The observed results revealed that the groups treated with MSC-Adp obtained smaller mucosal and submucosal lesions when compared to the groups treated with PBS. Also, MSC-Adp treated groups obtained controlled inflammatory response and higher mitotic rate, outcomes related to the therapeutic potential of MSC. Infusion of stem cells attenuated the lesions caused by intestinal I/R in both MSC groups when compared to the group treated with PBS.

4 March 2011 in Ciência Rural
Verified
Journal Article
Open access
EMEduardo Raposo Monteiro
Eduardo Raposo Monteiro
JSJuliano Ferreira Fernandes de Souza
Juliano Ferreira Fernandes de Souza
GBGustavo Cancian Baiotto
Gustavo Cancian Baiotto
GFGiuliano Moraes Figueiró
Giuliano Moraes Figueiró
JRJulia da Penha Piccoli Rangel
Julia da Penha Piccoli Rangel
CCClarisse S. Coelho
Clarisse S. Coelho
The influence of acepromazine (ACP) on the effectiveness of dobutamine (DBT) in increasing blood pressure during isoflurane (ISO) anesthesia was evaluated in six horses. On separate occasions, the horses were randomly assigned to receive NaCl 0.9% (Control), ACP 0.025mg kg-1 and ACP 0.05mg kg-1. The experimental treatment was administered prior to induction of anesthesia. Maintenance of anesthesia was performed under conditions of normocapnia with ISO in oxygen. Dobutamine was administered at progressively increasing infusion rates until mean arterial pressure (MAP) reached 70mmHg or until a maximum infusion rate of 5.0µg kg-1 min-1. Compared with baseline, DBT increased heart rate, systolic, diastolic and mean blood pressures in all treatments. However, these variables did not differ among treatments. The target MAP (70mmHg) was not reached in 2/6, 2/5 and 0/6 horses in the Control, ACP0.025 and ACP0.05 treatments, respectively. The mean dose of DBT to achieve target MAP was 3.5±1.8, 3.7±1.6 and 2.7±1.4µg kg-1 min-1 in the Control, ACP0.025 and ACP0.05 treatments, respectively (P>0.05). Under the conditions of this study, premedication with ACP does not interfere with the effectiveness of DBT in increasing blood pressure in horses anesthetized with ISO.

1 October 2016
Verified
Journal Article
Closed access
EMEduardo R Monteiro
Eduardo R Monteiro
RLRenan B Lobo
Renan B Lobo
JNJuarez S Nunes
Juarez S Nunes
JRJulia P P Rangel
Julia P P Rangel
FBFlavia S Bitti
Flavia S Bitti

26 December 2017 in Acta Scientiae Veterinariae
Verified
Journal Article
Open access
PDF file
EMEduardo Raposo Monteiro
Eduardo Raposo Monteiro
JPJuliana Barros Pinto
Juliana Barros Pinto
JSJuarez Simões
Juarez Simões
NJNunes Junior
Nunes Junior
JPJulia Da Penha
Julia Da Penha
PRPiccoli Rangel
Piccoli Rangel
Background: Acepromazine was found to reduce the incidence of vomiting induced by opioids such as morphine, hydromorphone and oxymorphone in dogs. Despite the effectiveness of the phenothiazine in preventing opioid-induced vomiting in this species, a single dose of acepromazine (0.05 mg/kg) was tested and the influence of dose on the antiemetic effect of the drug is unknown. The primary objective of this study was to evaluate the effect of three acepromazine doses on the incidence of vomiting induced by morphine in dogs. A secondary aim was to assess the degree of sedation and effects on physiological variables following administration of the combinations tested. Materials, Methods & Results: All dogs received 0.5 mg/kg morphine (IM). Fifteen min before morphine, dogs in the Control, ACPLD, ACPMD and ACPHD groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/kg, respectively. In Phase 1, purpose-bred dogs (n = 8) underwent each of the four treatments in a randomized, crossover design; the incidence of vomiting, sedation, pulse rate (PR), systolic, mean and diastolic blood pressures (SAP, MAP and DAP) were investigated for 60 min. Sedation was assessed by a numeric descriptive scale (NDS, range 0-3) and a simple numerical scale (SNS, range 1-10). In Phase 2, client-owned dogs (n = 50) received a single treatment and only the incidence of vomiting was assessed. There was no significant difference between groups on the incidence of vomiting recorded in Phase 1, Phase 2 and the average of Phases 1 and 2. A significant decrease in PR was observed in most groups but no significant difference was detected between groups. Blood pressure decreased in all groups; during most of the evaluation period, SAP, MAP and DAP were significantly higher in the Control than in other treatments. Dogs in this study presented mild to intense sedation. A significant difference in NDS scores was observed between the Control and ACPMD groups whereas for SNS scores, significant differences were detected between the ACPMD and ACPHD groups compared with the Control group. The number of dogs presenting intense sedation as judged by the NDS (NDS score = 3) were: 1/8, 3/8, 3/8 and 4/8 dogs in the Control, ACPLD, ACPMD and ACPHD groups, respectively. Discussion: The hypothesis of the study was rejected. The acepromazine dose did not influence the frequency of morphineinduced vomiting, the degree of sedation or cardiovascular variables after administration of either treatment. The frequency of vomiting was high (≥ 75%) in dogs of the present study regardless of the treatment administered. There was no significant difference in the frequency of vomiting in ACPLD, ACPMD and ACPHD as compared to the Control group. This finding was unexpected because it has been reported in a previous study that acepromazine reduced the incidence of opioid-induced vomiting in dogs. ACPLD, ACPMD and ACPHD improved the quality of sedation compared to the Control treatment but no significant difference in sedation scores was observed among these groups. These findings suggest that, when combined to morphine, there is no improvement in sedation when the acepromazine dose is increased above 0.025 mg/kg in dogs. Despite a significant decrease, mean values of PR, SAP, MAP and DAP remained within the physiological range for conscious dogs. In summary, none of the acepromazine doses was effective in preventing morphine-induced vomiting in dogs. Sedation is greater after acepromazine-morphine combinations than after morphine alone and is not influenced by the acepromazine dose. Cardiovascular effects induced by combinations administered in this study were well tolerated and of little clinical relevance to healthy conscious dogs.